Skip to content

US · BMEA · BIOTECHNOLOGY

Biomea Fusion, Inc. (BMEA) intrinsic value and stock valuation

$0.57as of 2026-11-21 · Mkt cap 91.1M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Biomea Fusion, Inc. DCF and intrinsic value

InvestorsCraft values BMEA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from BMEA’s statements →

Biomea Fusion, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Carlos, CA 94070 biomeafusion.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-61.8M
20192025
Free cash flow
-$-70.37M
20192025
Total equity
$29.6M+41.7% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-81.31M-$-144.07M-$-126.14M-$-83.63M-$-41.67M
Net income-$-61.8M-$-138.43M-$-117.25M-$-81.83M-$-41.57M
EPSd-$-1.18M-$-3.83M-$-3.44M-$-2.8M-$-1.74M
Operating cash flow-$-70.37M-$-119.89M-$-96.59M-$-62.42M-$-35.44M
Capital expenditure$0.00-$-360K-$-3.37M-$-1.03M-$-3.17M
Free cash flow-$-70.37M-$-120.26M-$-99.96M-$-63.45M-$-38.61M
Total assets$58.6M$79.9M$199.9M$129.3M$185.7M
Total debt$1.59M$8.77M$10.3M$2.29M$2.85M
Net debt-$-54.22M-$-49.51M-$-166.57M-$-109.61M-$-142.89M
Total equity$29.6M$51.6M$169.2M$108.5M$178.8M
Cash and short-term investments$55.8M$58.3M$176.9M$113.1M$173.5M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$1.41M$0.00$0.00$0.00$0.00
Gross profit-$-1.41M$0.00$0.00$0.00$0.00
Research and development expenses$62M$118.1M$102.6M$62.7M$28M
Selling, general and administrative expenses$19.3M$26M$23.6M$20.9M$13.7M
Other expenses-$-1.41M$0.00$0.00$0.00$0.00
Operating expenses$79.9M$144.1M$126.1M$83.6M$41.7M
Cost and expenses$81.3M$144.1M$126.1M$83.6M$41.7M
Interest income$1.86M$5.64M$8.88M$1.81M$100K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$1.41M$1.75M$1.51M$690K$250K
Ebitda-$-60.39M-$-136.68M-$-115.74M-$-81.14M-$-41.32M
Operating income-$-81.31M-$-144.07M-$-126.14M-$-83.63M-$-41.67M
Total other income/expenses, net$19.5M$5.64M$8.88M$1.81M$100K
Income before tax-$-61.8M-$-138.43M-$-117.25M-$-81.83M-$-41.57M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-61.8M-$-138.43M-$-117.25M-$-81.83M-$-41.57M
Weighted average shares outstanding$52.2M$36.1M$34.1M$29.3M$23.9M
Weighted average diluted shares outstanding$52.2M$36.1M$34.1M$29.3M$23.9M
Balance sheet
20252024202320222021
Cash and short-term investments$55.8M$58.3M$176.9M$113.1M$173.5M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$58.1M$68.3M$179.2M$117.8M$176.6M
Property, plant and equipment, net$150K$10.6M$14.9M$7.99M$5.69M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$370K$0.00$0.00$0.00$1.88M
Total non-current assets$520K$11.6M$20.8M$11.5M$9.14M
Total assets$58.6M$79.9M$199.9M$129.3M$185.7M
Accounts payable$3.23M$12.9M$6.85M$6.83M$1.33M
Short-term debt$1.46M$2.08M$2.47M$620K$560K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$11.1M$21.7M$22.9M$19.1M$4.64M
Long-term debt$130K$6.69M$7.83M$1.67M$2.29M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$17.9M$6.69M$7.83M$1.67M$2.29M
Capital lease obligations$1.59M$8.77M$10.3M$2.29M$2.85M
Total liabilities$29M$28.4M$30.7M$20.8M$6.92M
Common stock$10K$0.00$0.00$0.00$0.00
Retained earnings-$-449.05M-$-387.25M-$-248.82M-$-131.57M-$-49.74M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00-$0.00-$-10K
Total equity$29.6M$51.6M$169.2M$108.5M$178.8M
Total investments$370K$0.00$0.00$1.15M$29.7M
Total debt$1.59M$8.77M$10.3M$2.29M$2.85M
Net debt-$-54.22M-$-49.51M-$-166.57M-$-109.61M-$-142.89M
Cash flow statement
20252024202320222021
Net income-$-61.8M-$-138.43M-$-117.25M-$-81.83M-$-41.57M
Depreciation and amortization$1.41M$1.75M$1.51M$690K$250K
Stock-based compensation$9.52M$19.1M$14.1M$10.3M$6.23M
Change in working capital-$-3.7M-$-5.15M$2.33M$7.67M-$-1.57M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-9.7M$6.09M$2.56M$2.96M$640K
Net cash provided by operating activities-$-70.37M-$-119.89M-$-96.59M-$-62.42M-$-35.44M
Investments in property, plant and equipment$0.00-$-360K-$-3.37M-$-1.03M-$-3.17M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00-$-360K-$-2.22M$27.3M-$-33.35M
Common stock issued$67.9M$1.67M$161.8M$0.00$153.2M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$67.9M$1.67M$163.8M$1.24M$153.2M
Net change in cash-$-2.47M-$-118.59M$65M-$-33.84M$84M
Cash at end of period$56.2M$58.7M$177.2M$112.3M$145.7M
Operating cash flow-$-70.37M-$-119.89M-$-96.59M-$-62.42M-$-35.44M
Capital expenditure$0.00-$-360K-$-3.37M-$-1.03M-$-3.17M
Free cash flow-$-70.37M-$-120.26M-$-99.96M-$-63.45M-$-38.61M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Biomea Fusion, Inc.

        Biomea Fusion, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative covalent small molecule therapies. These treatments are specifically designed for individuals suffering from genetically defined cancers and various metabolic ailments. The company's primary drug candidate, BMF-219, is a potent and selective covalent inhibitor of menin, engineered for oral administration. Menin plays a crucial role as a transcriptional regulator in the abnormal signaling pathways found across numerous cancer types. Established in 2017, Biomea Fusion's operations are headquartered in Redwood City, California.

        CEO
        Michael J. Hitchcock
        Employees
        41
        Beta
        -0.33

        Explore

        Frequently asked questions

        What is the intrinsic value of Biomea Fusion, Inc. (BMEA)?

        InvestorsCraft does not currently publish an intrinsic value for BMEA. How the IC value is calculated.

        Is BMEA undervalued?

        InvestorsCraft does not publish an undervaluation signal for BMEA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.